Search
Sep 14
In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor
CEO Hervé Hoppenot describes the strategy for Incyte's PD1, and developing the CDK2 for ovarian and endometrial cancers, and possibly...
Dec 10, 2023
Incyte CEO Hervé Hoppenot on axatilimab for GvHD, BET inhibition, oral PD-1s and more from #ASH23
Hervé Hoppenot discusses Incyte's #ASH23 presentations, the company's pipeline, success in dermatology, and how he thinks about Jakafi.
.png){kind=logo}
